DCM
CLRB icon

Difesa Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Difesa Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-333
Closed -$34K – 246
2022
Q3 		$34K Buy
333
+300
+909% +$43.1K 0.02% 134
2022
Q2 		$40K Hold
33
– – 0.02% 134
2022
Q1 		$7K Hold
33
– – ﹤0.01% 234
2021
Q4 		$7K Buy
+33
New +$7.94K ﹤0.01% 224

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Difesa Capital Management's CLRB Position: Q4 2022 in Review

Difesa Capital Management sold out of Cellectar Biosciences (CLRB) in Q4 2022, closing a stake of 333 shares — an estimated $34K sold.

Difesa Capital Management first reported a position in CLRB in Q4 2021 and held it in 4 quarters. The position peaked at $40K in Q2 2022. 24 funds tracked by Wall St. Rank hold CLRB as of Q4 2022.

  • Difesa Capital Management reported no remaining Cellectar Biosciences position as of Q4 2022 after selling out during the quarter.
  • Difesa Capital Management sold 333 Cellectar Biosciences shares in Q4 2022, an estimated $34K.
  • Difesa Capital Management first reported a position in Cellectar Biosciences in Q4 2021 and held it in 4 quarters.
  • Difesa Capital Management's Cellectar Biosciences position peaked at $40K in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2022.

Based on Difesa Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.